Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis
- PMID: 20528340
- DOI: 10.1586/14737167.8.4.337
Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitis
Abstract
Aim: To evaluate patient perception of the onset of action and overall satisfaction with a fast-dissolving tablet (FDT) formulation of ebastine in patients with intermittent or persistent allergic rhinitis.
Patients and methods: This was a cross-sectional, multicenter, pharmacy-based survey involving adult patients (>18 years) with allergic rhinitis who presented with a prescription for ebastine FDT. Via a telephone interview, patients were asked to evaluate the characteristics of ebastine FDT in comparison with their previous experience with other antihistamines.
Results: 100 patients with allergic rhinitis were included in the study (41 had intermittent disease, 57 persistent disease and two with unknown disease states). Patients rated ebastine FDT very highly (mean scores: 4.5-4.7 out of a possible 5) for all characteristics related to convenience, such as easy to take, easy to carry around in a bag or pocket, suitable for taking anytime/anywhere, and convenient to use. A total of 85% of patients perceived ebastine FDTs onset of action to be fast or very fast, and 77% indicated that it acted faster than their usual antihistamine. A total of 96% were satisfied or very satisfied with ebastine FDT and 98% were interested in using the drug again.
Conclusions: Patients with rhinitis rate ebastine FDT very highly in terms of its formulation, convenience of use and its rapid onset of action. These characteristics resulted in a high level of individual satisfaction with the new formulation and a clear preference by the majority of patients to use ebastine FDT in the future.
Similar articles
-
Ebastine fast-dissolving tablets versus regular tablets: acceptability and preference in patients with allergic rhinitis.Expert Rev Clin Pharmacol. 2008 May;1(3):381-9. doi: 10.1586/17512433.1.3.381. Expert Rev Clin Pharmacol. 2008. PMID: 24422693
-
Ebastine in allergic rhinitis and chronic idiopathic urticaria.Allergy. 2008 Dec;63 Suppl 89:1-20. doi: 10.1111/j.1398-9995.2008.01897.x. Allergy. 2008. PMID: 19032340 Review.
-
[Multicenter study of satisfaction with fast-dissolving ebastine, 20 mg/ day, in Mexican patients with allergic rhinitis].Rev Alerg Mex. 2009 Mar-Apr;56(2):36-40. Rev Alerg Mex. 2009. PMID: 19526952 Clinical Trial. Spanish.
-
Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies.Allergol Immunopathol (Madr). 2006 May-Jun;34(3):107-12. doi: 10.1157/13088176. Allergol Immunopathol (Madr). 2006. PMID: 16750120
-
Rupatadine in allergic rhinitis and chronic urticaria.Allergy. 2008 Apr;63 Suppl 87:5-28. doi: 10.1111/j.1398-9995.2008.01640.x. Allergy. 2008. PMID: 18339040 Review.
Cited by
-
Clinical utility and patient adherence with ebastine for allergic rhinitis.Patient Prefer Adherence. 2010 Oct 14;4:389-95. doi: 10.2147/PPA.S8186. Patient Prefer Adherence. 2010. PMID: 21206514 Free PMC article.
-
Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters.ScientificWorldJournal. 2022 May 19;2022:9618344. doi: 10.1155/2022/9618344. eCollection 2022. ScientificWorldJournal. 2022. PMID: 35645632 Free PMC article.
-
Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.J Asthma Allergy. 2009 Aug 31;2:73-92. doi: 10.2147/jaa.s3108. J Asthma Allergy. 2009. PMID: 21437146 Free PMC article.
LinkOut - more resources
Full Text Sources